Curium Announces First Commercial Doses of diagnostic radiopharmaceuticals in Czech Republic and Slovakia for Patients with Prostate Cancer

• Curium has entered a partnership with the Czech company ÚJV Řež, a leading expert in the development and production of radiopharmaceuticals, to manufacture diagnostic radiopharmaceuticals for patients with prostate cancer in both Czech Republic and Slovakia
• This will provide solutions to a wider patient group across both countries where there is high demand and unmet need

(Paris, France – 06 November 2025) – Curium, a world leader in nuclear medicine, has announced that patients in Czech Republic and Slovakia received the first doses of diagnostic radiopharmaceuticals used to indicate detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer.

Curium entered a partnership with ÚJV Řež, a leading expert in the development and production of radiopharmaceuticals, to manufacture diagnostic radiopharmaceuticals locally for both countries.  Following a successful technology transfer earlier this year, these doses are now being produced at ÚJV Řež facilities in Řež and Brno. This collaboration will not only enable local production but will also make the product available to neighboring countries, further expanding the access to the compound.

Distribution of the product is managed by Curium’s long-standing partners KC Solid and Lacomed.

Aydin Küçük, Senior Vice President, Curium Growth Markets, said: “We are extremely pleased with today’s news that PYLCLARI^® is now available to patients with prostate cancer in Czech Republic and Slovakia, through our manufacturing partnership with ÚJV Řež.  Our combined expertise allowed for a fast setup of sites and processes, and we now have a very robust infrastructure to make PYLCLARI^® available in the region.  As we continue to redefine the experience of cancer through our trusted legacy in nuclear medicine, the growing availability of PYLCLARI^® in Europe is improving the choice of diagnostic radiopharmaceuticals available to physicians to better diagnose and monitor prostate cancer – ultimately for the benefit of our patients.”